7th Neuropsychiatric Drug Development Summit

Temi della conferenza
With Karuna's schizophrenia program coined as the most anticipated drug launch of 2024, and 2023 bringing brand new regulatory guidance, surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape.

Professional congress organizer (PCO)
Hanson Wade Group

Annotazioni
URL:
Brochure: https://go.evvnt.com/2433814-3?pid=4832

Speakers: Aaron Koenig, Chief Medical Officer, Delix Therapeutics, Ariana Mullin, Director, Regulatory Affairs, Bristol Myers Squibb, and more

https://go.evvnt.com/2433814-2?pid=4832

Ms. Erin Thomas